Ralmitaront
Ralmitaront (, ; developmental code names RG-7906 and RO-6889450) is an investigational antipsychotic drug which is undergoing a clinical trial for the treatment negative symptoms in schizophrenia and schizoaffective disorder. Another clinical trial targeting acute psychotic symptoms of schizophrenia has been terminated due to lack of efficacy. It is a partial agonist of the TAAR1. The medication is being developed by the pharmaceutical company Hoffmann-La Roche. Ralmitaront had completed phase 1 clinical trials. See also 

 List of investigational antipsychotics § Monoamine receptor modulators

References 

Antipsychotics
Carboxamides
Experimental drugs
Morpholines
Pyrazoles
TAAR1 agonists